| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |